This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2011 Mar;25(3):300, 302.

Sorafenib for HCC: a pragmatic perspective

Nataliya Razumilava¹, Gregory J Gores

Affiliations

PMID: 21548475

Free article

Review

Sorafenib for HCC: a pragmatic perspective

Nataliya Razumilava et al. Oncology (Williston Park). 2011 Mar.

Free article

. 2011 Mar;25(3):300, 302.

Authors

Nataliya Razumilava¹, Gregory J Gores

Affiliation

¹ Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA.

PMID: 21548475

No abstract available

PubMed Disclaimer

Comment on

What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
Kim R, Byrne MT, Tan A, Aucejo F. Kim R, et al. Oncology (Williston Park). 2011 Mar;25(3):283-91, 295. Oncology (Williston Park). 2011. PMID: 21548473 Review.

Similar articles

Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?
Burak KW. Burak KW. Oncology (Williston Park). 2011 Mar;25(3):296, 298, 300. Oncology (Williston Park). 2011. PMID: 21548474 Review. No abstract available.
Hepatocellular carcinoma: sorafenib before liver transplantation?
Braillon A. Braillon A. Hepatology. 2010 Jun;51(6):2232-3. doi: 10.1002/hep.23439. Hepatology. 2010. PMID: 20041410 No abstract available.
What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
Kim R, Byrne MT, Tan A, Aucejo F. Kim R, et al. Oncology (Williston Park). 2011 Mar;25(3):283-91, 295. Oncology (Williston Park). 2011. PMID: 21548473 Review.
Sorafenib in hepatocellular carcinoma.
Josephs DH, Ross PJ. Josephs DH, et al. Br J Hosp Med (Lond). 2010 Aug;71(8):451-6. doi: 10.12968/hmed.2010.71.8.77669. Br J Hosp Med (Lond). 2010. PMID: 20852487 Review.
Health-related quality of life and sorafenib.
Spinzi G, Terreni N. Spinzi G, et al. Hepatology. 2010 Oct;52(4):1523. doi: 10.1002/hep.23756. Hepatology. 2010. PMID: 20672386 No abstract available.

See all similar articles

Cited by

Prediction and analysis of weighted genes in hepatocellular carcinoma using bioinformatics analysis.
Zhang Q, Sun S, Zhu C, Zheng Y, Cai Q, Liang X, Xie H, Zhou J. Zhang Q, et al. Mol Med Rep. 2019 Apr;19(4):2479-2488. doi: 10.3892/mmr.2019.9929. Epub 2019 Feb 4. Mol Med Rep. 2019. PMID: 30720105 Free PMC article.
Long non-coding RNA Myd88 promotes growth and metastasis in hepatocellular carcinoma via regulating Myd88 expression through H3K27 modification.
Xu X, Yin Y, Tang J, Xie Y, Han Z, Zhang X, Liu Q, Qin X, Huang X, Sun B. Xu X, et al. Cell Death Dis. 2017 Oct 12;8(10):e3124. doi: 10.1038/cddis.2017.519. Cell Death Dis. 2017. PMID: 29022910 Free PMC article.
6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib.
Liu Y, Lou G, Norton JT, Wang C, Kandela I, Tang S, Shank NI, Gupta P, Huang M, Avram MJ, Green R, Mazar A, Appella D, Chen Z, Huang S. Liu Y, et al. FASEB J. 2017 Dec;31(12):5453-5465. doi: 10.1096/fj.201700306RR. Epub 2017 Aug 17. FASEB J. 2017. PMID: 28821631 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- UBM Medica LLC
Medical
- MedlinePlus Health Information